56. L
ewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic
patients treated with pioglitazone: interim report of a longitudinal cohort
study. Diabetes Care. 2011;34(4):916-24.
57. N
eumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone
and risk of bladder cancer among diabetic patients in France: a population-
based cohort study. Diabetologia. 2012;55(7):1953-62
58. A
ubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone
and pioglitazone increase fracture risk in women and men with type 2
diabetes. Diabetes Obes Metab. 2010;12(8):716-21
59. H
emmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for
patients with type 2 diabetes mellitus. Cochrane Database Syst Rev.
2013;4:CD009008
60. K
alra S, et al. Place of sulfonylureas in the management of type 2 diabetes